Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Brexpiprazole 4 mg vs RXULTI in healthy adults
NCT07266792Phase 1Completed
- Sponsor
- Humanis
- Start
- Jun 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of brexpiprazole orally disintegrating tablet in schizophrenia (2 arms), sponsored by Humanis. Primary endpoints: Maximum measured plasma concentration at 72 hours and Area under the plasma concentration-time curve from time point to 72 hours. Started Jun 2025; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07266792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07266792.